These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 22911364)

  • 1. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
    Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
    Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
    Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
    Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma.
    Hsieh SY; Huang SF; Yu MC; Yeh TS; Chen TC; Lin YJ; Chang CJ; Sung CM; Lee YL; Hsu CY
    Mol Carcinog; 2010 May; 49(5):476-87. PubMed ID: 20232364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
    Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
    Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
    Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
    Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
    Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
    Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
    Zhou D; Masri S; Ye JJ; Chen S
    Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
    Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
    Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
    Kang J; Huang X; Dong W; Zhu X; Li M; Cui N
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S257-S268. PubMed ID: 34420405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
    Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
    J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway.
    Sun HX; Xu Y; Yang XR; Wang WM; Bai H; Shi RY; Nayar SK; Devbhandari RP; He YZ; Zhu QF; Sun YF; Hu B; Khan M; Anders RA; Fan J
    Hepatology; 2013 Mar; 57(3):1088-97. PubMed ID: 23212661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation.
    Zhang W; Zhou L; Ding SM; Xie HY; Xu X; Wu J; Chen QX; Zhang F; Wei BJ; Eldin AT; Zheng SS
    Oncol Rep; 2011 Apr; 25(4):1053-62. PubMed ID: 21271221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.
    Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A
    Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter.
    Tomizawa M; Yu L; Wada A; Tamaoki T; Kadomatsu K; Muramatsu T; Matsubara S; Watanabe K; Ebara M; Saisho H; Sakiyama S; Tagawa M
    Br J Cancer; 2003 Sep; 89(6):1086-90. PubMed ID: 12966430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.
    Xia L; Mo P; Huang W; Zhang L; Wang Y; Zhu H; Tian D; Liu J; Chen Z; Zhang Y; Chen Z; Hu H; Fan D; Nie Y; Wu K
    Carcinogenesis; 2012 Nov; 33(11):2250-9. PubMed ID: 22831955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
    Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
    Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
    Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
    Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1.
    Liu YP; Pan LL; Kong CC
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.